open access

Vol 64, Supp. II (2014)
Supplement
Published online: 2014-05-14
Get Citation

The use of vemurafenib in BRAF-positive metastatic melanoma patients — selected cases reports

DOI: 10.5603/NJO.2014.0016

open access

Vol 64, Supp. II (2014)
Supplement
Published online: 2014-05-14

Abstract

The incidence of cutaneous melanoma is constantly increasing. The primary treatment in early stage of disease re­mains surgery. New therapeutic strategies such as immunotherapy or selective BRAF inhibitors — vemurafenib and dabrafenib, have improved outcomes of treatment in the group of patients with stage IV melanoma. In Poland still only vemurafenib is available in routine clinical practice. In this article we present clinical experiences in treating of BRAF-positive metastatic melanoma patients with use of vemurafenib.

Abstract

The incidence of cutaneous melanoma is constantly increasing. The primary treatment in early stage of disease re­mains surgery. New therapeutic strategies such as immunotherapy or selective BRAF inhibitors — vemurafenib and dabrafenib, have improved outcomes of treatment in the group of patients with stage IV melanoma. In Poland still only vemurafenib is available in routine clinical practice. In this article we present clinical experiences in treating of BRAF-positive metastatic melanoma patients with use of vemurafenib.

Get Citation
About this article
Title

The use of vemurafenib in BRAF-positive metastatic melanoma patients — selected cases reports

Journal

Nowotwory. Journal of Oncology

Issue

Vol 64, Supp. II (2014)

Pages

1-19

Published online

2014-05-14

DOI

10.5603/NJO.2014.0016

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl